| Literature DB >> 34249856 |
Keshavananda Prabhu C P1, Manjunatha Nemakal1, Muthumuni Managa2, Tebello Nyokong2, Lokesh Koodlur Sannegowda1.
Abstract
N4 macrocyclic complexes ofEntities:
Keywords: infrared spectra; photodynamic therapy; phthalocyanine; quantum yield; singlet oxygen
Year: 2021 PMID: 34249856 PMCID: PMC8263923 DOI: 10.3389/fchem.2021.647331
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
FIGURE 1Schematic illustration for the application of phthalocyanine in photodynamic therapy study (PDT).
SCHEME 1(A) Synthetic route of (VIIIa–b) ligands. (B) Synthetic route of (VIIIc–e) ligands.
SCHEME 2(A)Synthetic route of (IXa–d) phthalocyanine complexes. (B) Synthetic route of (IXe-f) phthalocyanine polymers.
FIGURE 2UV–visible spectra of (IXa–f) in DMSO.
FIGURE 3FT-IR spectra of IIIa, IIIb, and VIa-c precursors.
FIGURE 4FT-IR spectra of (VIIIa-e) phthalonitrile ligands.
FIGURE 5FT-IR spectra of (IXa-f) phthalocyanines.
FIGURE 6Mass spectrum for phthalocyanine IXb with mass fragment (M-3) = 1402.
FIGURE 7Mass spectrum for phthalocyanine IXc with mass fragment (M.) = 1526; (M+1) = 1527; and (M+3) = 1529.
FIGURE 8Mass spectrum for phthalocyanine IXd with mass fragment (M-2) = 1305.
FIGURE 9Dark toxicity plots for Pcs at 0, 10, 20, 40, 80, and 100 μg/ml.
FIGURE 10PDT for Pcs at 0, 10, 20, 40, 80, and 100 μg/ml.